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The therapeutic potential of bone marrow-derived
mesenchymal stem cells on hepatic cirrhosis
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c RDx Life Sciences Ltd, Shenzhen, Guangdong, ChinaReceived 16 April 2008; received in revised form 11 July 2008; accepted 31 July 2008Abstract Hepatic cirrhosis is the end-stage of chronic liver diseases. The majority of patients with hepatic cirrhosis die
from life-threatening complications occurring at their earlier ages. Liver transplantation has been the most effective
treatment for these patients. Since liver transplantation is critically limited by the shortage of available donor livers,
searching for an effective alternative therapy has attracted great interest in preclinical studies. The transplantation of
autologous bone marrow-derived mesenchymal stem cells holds great potential for treating hepatic cirrhosis. Mesenchymal
stem cells can differentiate to hepatocytes, stimulate the regeneration of endogenous parenchymal cells, and enhance
fibrous matrix degradation. Experimental and clinical studies have shown promising beneficial effects. This review is intended
to translate the bench study results to the patients' bedside. The potential interventions of mesenchymal stem cells on
cirrhosis are illustrated in terms of the cellular and molecular mechanisms of hepatic fibrogenesis.
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Cirrhosis represents the final common pathological outcome
for the majority of chronic liver diseases. Most patients with
cirrhosis die from one or more clinical complications
including ascites, hepatic encephalopathy, and variceal
hemorrhage (Bataller and Brenner, 2005). Among the 1.4
million liver disease-related deaths each year worldwide,
over 55%, or 796 000, are directly attributable to cirrhosis
(Poynard et al., 2003). The majority of chronic liver diseases
are initiated by the infection of hepatitis B virus (HBV) and
hepatitis C virus (HCV) (Lai et al., 2003; Poynard et al.,
2003). Liver transplantation has been the most effective
therapy for the patients with advanced liver diseases.
Unfortunately, most patients are unable to obtain transplan-
tation due to the limited availability of donor livers. Over
10% of patients die while waiting for liver transplantation.
Among the fortunate patients who received liver transplants,
the survival rate has been 94% at 3 months, 88% at 1 year and
79% at 3 years (Freeman et al., 2008). Thus, it is of great
interest to search for an effective alternate to treat this
type of life-threatening disease. Recently, stem cell-based
cytotherapy has shown promising benefit on animal models
and some clinical patients. This review highlights recent
progress in this field, emphasizing the therapeutic potential
of bone marrow-derived mesenchymal stem cells (MSCs) on
hepatic cirrhosis.
Pathogenesis of liver cirrhosis
Hepatic fibrosis refers to the excessive accumulation of
extracellular matrix (ECM) with the formation of scar tissue
encapsulating the area of injury. Actually, it is a wound-
healing response of the liver to either acute or chronic liver
injury (Guo and Friedman, 2007). Cirrhosis, the end-stage of
progressive fibrosis, is characterized by septum formation
and rings of scar that surround the nodules of hepatocytes.
Accumulation of ECM results from both increased synthesis
and decreased degradation of ECM.
Cellular sources of ECM in cirrhotic liver
Hepatic stellate cells (HSCs) are the main ECM-producing
cells in the injured liver. HSCs reside in the space of Disse
and are the major storage sites of vitamin A. When a liver
injury occurs (e.g., viral hepatitis), HSCs proliferate and
undergo a dramatic phenotypical alteration, which is
characterized by the acquisition of a proliferative, con-
tractile, migratory, fibrogenic and inflammatory pheno-
type. Activated HSCs secrete large amount of ECM proteins,
including collagen (I, III, and IV), fibronectin, undulin,
elastin, laminin, hyaluronan, and proteoglycans (Bataller
and Brenner, 2005). The accumulating interstitial ECM
constituents that collectively form the hepatic scar replace
the low-density type IV collagen with the normal sub-endothelial space of Disse. These interstitial fibril-forming
collagens (especially types I and III collagens) become
distributed primarily in the connective septa surrounding
the regenerative hepatic nodules. A cirrhotic liver may
contain up to six times more collagen and proteoglycan than
a healthy organ (Friedman, 2008). In addition to the
resident HSCs, periportal fibroblasts, bone marrow-derived
fibrogenic cells, epithelial-mesenchymal transition, and
possibly circulating fibrocytes can contribute to the
fibrogenesis in the liver (Friedman, 2008). The relative
importance of each cell type in liver fibrogenesis depends
on the origin of liver injury. While HSCs are the main
fibrogenic cell type in pericentral areas, periportal fibro-
blasts predominate when liver injury occurs around portal
tracts. Since the majority of patients with chronic liver
diseases are induced by HBV and HCV infection (Lai et al.,
2003; Poynard et al., 2003), HSC-mediated pericental
fibrosis plays an important role in the development of
hepatic cirrhosis. Therefore, prevention of HSC activation
has been the most promising therapeutic strategy for this
disease.
Some other cell types also contribute to the progression of
liver fibrosis. These include liver resident cell types (for
example, hepatocytes, Kupffer cells, sinusoidal endothelial
cells, and bile duct epithelial cells, etc.) and non-resident or
circulating cells (for example, T and B lymphocytes). They
may not secrete ECM proteins directly, but upon being
damaged they activate HSCs through a variety of inflamma-
tory mediators, apoptotic bodies, free radicals, and fibro-
genic cytokines (Duffield et al., 2005; Canbay et al., 2004;
Jarnagin et al., 1994; Sedlaczek et al., 2001).
Molecular regulations of ECM accumulation
Numerous factors are involved in liver ECM synthesis and/or
degradation, including growth factors, cytokines, and
chemokines. They play direct or indirect roles in fibrogenesis
or anti-fibrogenesis depending on their effects and targets.
For example, matrix metalloproteinases (MMPs) are directly
responsible for matrix breakdown, and an increase of tissue
inhibitors of metalloproteinases (TIMPs) indirectly favors the
accumulation of ECM. Table 1 lists some liver fibrogenesis-
related factors, in which the origin, possible target and
mechanism are indicated. The general molecular basis of
fibrosis has been summarized in a recent review (Wynn,
2008).
The expression of inflammatory mediators determines the
fibrogenic response to liver injury. Hepatocytes are the
targets of most hepatotoxic agents, including hepatitis
viruses, alcohol metabolites, and bile acids (Higuchi and
Gores, 2003). Damaged hepatocytes and involved inflamma-
tory cells release a variety of inflammatory mediators. A
number of fibrogenic molecules listed in Table 1 are also
inflammatory mediators, such as free radicals, IL-1b, IL-6, IL-
10, IL13, IFN-γ, SOCS-1, and osteopontin (Sahai et al., 2004;
Bataller and Brenner, 2005). Inflammatory molecules
ing transplant for liver disease (Kao et al., 2007). The ideal
Table 1 Liver fibrogenesis-related factors
Factors Origin ⁎ Target Possible effect Reference
Fibrogenicz
TIMPs N, L MMP, HSC inhibit MMPs and activate HSC Murphy et al., 2002
Apoptotic body H HSC activate HSC Friedman, 2008
Free radicals H, K, M HSC activate HSC Bataller et al., 2003
TGF-β1 H, K TIMP-1,ECM up-regulate TIMP-1, down-regulate colagenase I Shek and Benyon, 2004
TNF-α H, K, B, M HSC activate HSC Bataller and Brenner, 2005
IGF H, K HSC activate HSC Bataller and Brenner, 2005
PDGF B, K, P HSC activate HSC Borkham-Kamphorst et al., 2004
FGF H, D HSC activate HSC Yu et al., 2003
ANG II M, F NADPH activate HSC through free radicals and TGF-ß1 Bataller et al., 2003
Endothelin-1 B HSC activate HSC Bataller and Brenner, 2005
IL-4 L HSC, TIMP-1 up-regulate TIMP-1, activate HSC Cheever et al., 1994
IL-5 E HSC activate HSC Cho et al., 2004
IL-6 L,K, HSC HSC activate HSC Hasegawa et al., 2005
IL-13 E, L HSC collagen deposition Reiman et al., 2006
IL-21 L Macrophage increase IL-4 and IL-13 receptor expression Pesce et al., 2006
Anti-fibrogenic
MMPs M, D ECM,HSC ECM degradation, HSC apoptosis Wynn, 2007
HGF H HSC HSC apoptosis Parekkadan et al., 2007a,b
IL-10 L HSC suppress the synthesis of type I collagens Wangoo et al., 1997
IL-12 L Fibrocyte inhibit fibrocyte differentiation Shao et al., 2008
IFN-γ L Fibrocyte inhibit fibrocyte differentiation Wynn, 2007
⁎ B: Biliary Cell; D: Endothelial Cell; E: Eosinophil; F: Fibroblast; H: Hepatocyte; K: Kupffer Cell; L: Lymphocyte; M: Macrophage; N:
Neutrophil; P: Platelet.
18 L.-J. Dai et al.activate HSCs, and the resulting activated HSCs secrete
inflammatory chemokines, express cell adhesion molecules,
and modulate the activation of inflammatory cells (Viñas
et al., 2003). Therefore, a vicious circle exist between
inflammatory and fibrogenic cells. Any approach able to
break this circle can presumably lead to the development of
an anti-fibrotic treatment.
Reversibility of hepatic cirrhosis
Hepatic cirrhosis is traditionally thought to be irreversible.
However, recent evidence from animal studies and human
clinical observations indicate that even advanced fibrosis is
still reversible (Arthur, 2002; Issa et al., 2004). The most
effective intervention in the treatment of liver fibrosis is
to remove the causative agents, such as the utilization of
anti-viral therapy and the obstruction of alcohol intake. It
may take years for significant recovery to be achieved; the
time varies depending on the underlying cause of the liver
injury and its severity. It is unlikely to reach a complete
return to normal histology. So, the term of “regression” is
more relevant to the real situation rather than “reversal”
(Friedman, 2007). As described above, liver fibrosis results
from the imbalance between ECM production and ECM
degradation. Theoretically, any approach which decreases
ECM synthesis and/or increases ECM degradation could
accelerate the regression of hepatic fibrosis/cirrhosis. For
example, the inhibition of activated HSCs by modulating
their activation and/or proliferation or the promotion of
their apoptosis would be a useful strategy.The potential effects of mesenchymal stem
cells on hepatic cirrhosis
Since the bone marrow-derived mesenchymal stem cells
(MSC) were found to have differentiative plasticity, there has
been great interest in their potential therapeutic application
(Jiang et al., 2002). The feature of self-origin and readily ex
vivo expansion renders MSC autotransplantation a practical
approach. There is increasing evidence indicating the
therapeutic benefit of MSC transplantation in various
disorders characterized by cell injury or cell loss, such as
ischemic heart diseases (Assmus et al., 2006) and stroke
(Chopp and Li, 2002; Bang et al., 2005). Some encouraging
results were also obtained from our own clinical trials on the
patients with traumatic brain injury and acute myocardial
infarction (Zhang et al., 2008, 2007b). Nevertheless, the
investigation of applying MSC to liver diseases is not as
advanced as in other fields. Upon liver injury, the typical
repair process involves two distinct phases: a regenerative
phase, in which injured liver cells are replaced with
regenerated hepatocytes; and a phase known as fibroplasias
or fibrosis, in which connective tissue replaces normal
parenchymal tissue. Although initially beneficial, the repair
process becomes pathogenic when it is not controlled
appropriately. Extensive accumulation of ECM components
can ultimately lead to cirrhosis and liver failure (Wynn,
2008). Moreover, fibronectin, a component of ECM, has been
proved to promote the MSC-induced cytoprotection follow-
19Mesenchymal stem cells and hepatic cirrhosisstrategy to treat liver injury is to generate new hepatocytes
replacing damaged cells without causing excessive ECM
deposition.MSC replace hepatocytes in injured liver
Hepatocyte-like differentiation
The first demonstration of the existence of putative liver
stem cells in the bone marrow was reported by Petersen et al
in 1999 (1999). They showed that bone marrow cells
transplanted into lethally irradiated mice engrafted in the
recipient's liver and differentiated into liver stem cells (oval
cells) or mature hepatocytes. These in vivo results were
confirmed in animal models and in patients who received
bone marrow transplantation for hematological disorders
(Theise et al., 2000; Alison et al., 2000). Hematopoietic stem
cells consist of the majority of stem cell population in the
bone marrow, while nonhematopoietic, i.e. mesenchymal
stem cells (MSC) are only a very small fraction of the
population, representing 0.001–0.01% of the nucleated cells
in adult human bone marrow (Pittenger et al., 1999).
Although these two cell types are reported to differentiate
into cell lineages of all three germ layers, i.e. ectoderm,
mesoderm and endoderm (Yen et al., 2006), MSCs show
different characteristics compared to other components in
differentiating into hepatocytes (Sato et al., 2005). Schwartz
and colleagues (2002) provided direct evidence of in vitro
hepatogenic differentiation of MSC. A subpopulation of MSC
isolated from bone marrow of human, mouse and rat,
cultured on Matrigel with FGF-4 and HGF, differentiated
into hepatocyte-like cells. These cells express hepatic
markers, i.e. HNF-3β, GATA4, CK19, transthyretin,
α-fetoprotein, albumin and CK18. They also possess func-
tional characteristics of hepatocytes, i.e. secreting urea and
albumin, having phenobarbital-induced cytochrome p450,
taking up LDL and storing glycogen. In vitro liver-specific
differentiation of MSC can also be induced by co-culture with
liver cells (Lange et al., 2005) and pellet culture (Ong et al.,
2006a). Although hepatocyte-induction protocols work well
in cultured MSC, an organ-specific microenvironment is the
most suitable place for them to differentiate into required
cell types. Sato et al. (2005) demonstrated the first in vivo
hepatic differentiation of MSC . In that study, human bone
marrow-derived MSCs were directly xenografted to allylalco-
hol-treated rat liver, and the most human MSC-differentiated
hepatocyte-like cells were observed at day 28, as revealed by
positive immunostaining for human specific AFP, albumin,
CK19, CK18 and asialoglycoprotein receptor. A recent study
by Chamberlain et al. (2007) provided further evidence of in
vivo hepatic differentiation of MSC. Clonal human MSCs were
xenotransplanted to fetal sheep liver by intrahepatic injec-
tion in their study. A widespread distribution of human MSC-
originated hepatocytes throughout the liver parenchyma was
exhibited at days 56–70. In addition to the bone marrow-
derived MSC, hepatogenic differentiation of MSCs from other
sources, such as adipose tissue (Seo et al., 2005), umbilical
cord blood (Hong et al., 2005) or commercially available MSCs
(Ong et al., 2006b) have also been achieved. It is worth noting
that a significant problem for stem cell research is the
interpretation of in vitro data concerning the content of
hepatic differentiation, which is often problematic andcontroversial (Fox and Strom, 2008). Useful stem cell-derived
hepatocytes will need to not only express the genes found in
mature liver cells, but the level of the expression need to be
at or near those found in the normal liver.
The gene signaling pathways in hepatic differentiation are
essential for MSC-based therapies for the treatment of
cirrhotic liver disease. Hepatic-differentiated cells are
characterized by the expression of hepatocyte-specific
genes. This specific gene expression is ingeniously regulated
by numerous transcription factors and is also influenced by
microenvironmental conditions. Costa et al. (2003) elabo-
rated the transcription factors in liver development,
differentiation and regeneration. Recently, Yamamoto
et al. (2008) demonstrated the hepatic differentiation of
human adipose tissue-derived MSCs. They utilized microarray
analysis to identify the genes responsible for hepatic
differentiation and found evidence of transdifferetiation
through mesenchymal-epithelial transition in the process of
hepatic differentiation. Further studies identifying the
complex network of interaction between gene signals during
hepatic differentiation of MSCs may facilitate the develop-
ment of novel methods of therapeutic intervention in human
liver cirrhosis.
Homing and functional integration
The potential therapeutic benefit of MSCs can only be
realized through their homing efficiency to the required site.
Although the ultimate success or failure of cell therapy will
rest on its ability to show clinical efficacy rather than the
underlying mechanism, a variety of evidence from clinical
and animal studies has indicated that MSC's direct differen-
tiation and indirect effect through its secretion play
important roles in promoting tissue recovery. An animal
study by Aurich et al. (2007) showed the functional
integration of MSC-differentiated hepatocytes in the liver.
Human MSCs were pre-differentiated and directly trans-
planted into immunodeficient mouse liver. Engraftment of
transplanted pre-differentiated human MSCs in the mouse
liver was observed three weeks after transplantation.
Functional hepatic integration was also revealed using un-
differentiated human MSCs xenografted directly onto rat
liver (Sato et al., 2005).
The following questions have been frequently encoun-
tered while pursuing cell-based therapeutic investigations:
what is the best method of delivery of cells, how do the cells
get to the sites of injury and by what mechanisms are they
targeted? As previously discussed, the methods of MSC
administration can be classified into three categories,
directional or site-specific delivery, semi-directional
delivery, and systemic delivery (Zhang et al., 2008). Among
above examples, Sato et al. (2005) administered MSCs to the
injured liver by intrahepatic injection, which is considered as
directional delivery; intrasplenic injection by Aurich et al.
(2007) and intravenous infusion by Fang et al. (2004) are
examples of semi-directional and systemic deliveries. Under
certain circumstances, the combination of more than one
method and repeated administration may also be
considered. The migration of MSC from the circulation into
damaged or pathological tissues is the most crucial step
bringing MSC into play. Biological signals released from the
injured area and corresponding receptors expressed on the
cell surface of MSC are critical determinants in this step.
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liver injury, the timing and numbers of MSC homing to the
liver are closely related to the presence of liver injury but
not to the route of MSC infusion, e.g., through the tail vein or
the portal vein. The process of leucocyte homing to specific
inflammatory sites in response to inflammatory stimuli is a
well characterized sequential process, which involves
selectins, chemokines, integrins and other adhesion mole-
cules. As MSCs are known to be selectively recruited to
injured tissue it can be reasonably assumed that they utilize
comparable mechanisms of recruitment, i.e. transendotelial
migration directed by chemokine gradient (Fox et al., 2007).
This assumption has been evidenced in the studies of
myocardial infarction (Abbott et al., 2004) and ischemic
brain injury (Wang et al., 2002). The detailed process of
transendothelial migration of MSC was elaborated in a recent
review (Fox et al., 2007). It is worth noting that MSC
chemokine receptor expression has been shown to diminish
with in vitro culture and decreased receptor expression
leads to a corresponding decrease in chemotactic respon-
siveness of the cells (Honczarenko et al., 2006).
The functional recovery of injured liver is proportionally
relevant to the amount of hepatic regeneration. At least 2.5
to 5% of a human liver needs to be replaced by healthy cells
to reverse a pathological condition (Fox et al., 1998).
However, most transplantation studies have indicated that
MSC-derived hepatocytes did not comprise more than 1% of
the total liver mass. One plausible explanation for this low
efficiency is the heterogeneity of MSCs employed in the
studies. Due to the xenogeneic nature of the transplantation,
a considerable number of inoculated MSCs might have been
rejected even in an immunosuppressive state. This viewpoint
is consistent with Chamberlain's recent finding in a pre-
immune fetal animal model (Chamberlain et al., 2007).
Human MSC-derived hepatocytes comprised over 12% of the
total liver mass after xenotransplanted into fetal sheep liver.
Apparently, homing efficiency of MSC could be greatly
improved by autologous transplantation. A recent case
report describes the use of autologous unsorted bone marrow
stem cells as rescue treatment for hepatic failure in a 67-
year-old man ineligible for liver transplantation (Gasbarrini
et al., 2007). Apparent rapid improvement in hepatic
synthetic function was obtained after the portal venous
infusion of the cells. A liver biopsy performed 20 days after
cell transplant was reported as showing increased hepato-
cyte replication around necrotic foci, although transplanted
cells were not identifiable as they were not labeled with
markers before transplantation. In addition to the direct
hepatic differentiation of implanted stem cells in the injured
area, MSC paracrine-mediated hepatic regeneration from
endogenous liver stem cells may also contribute to the
hepatocyte replication and recovery of hepatic function.
Parekkadan et al. (2007b) reported the first experimental
evidence of therapeutic use of MSC paracrine. A significant
survival benefit was observed by MSC-conditioned medium
perfusion in Gal-N-induced fulminant hepatic failure rat
model. More recently, van Poll et al. (2008) provided further
evidence that MSC-derived molecules directly inhibit hepa-
tocellular death, enhance liver regeneration and ultimately
improve survival in rats undergoing D-galactosamine-induced
fulminant hepatic failure. These investigations validate the
therapeutic benefits of MSC-derived molecules on liverdisease and may create potential new avenues for the
treatment of advanced liver disorders.
MSC attenuate the progression of hepatic
fibrogenesis
As described earlier, hepatic fibrosis or cirrhosis results from
the imbalance of ECM production and degradation. Any
approach that resets the balance could lead to the resolution
of fibrogenic liver disorders. The fact that MSC have
antifibrosis effects in injured liver has been clearly demon-
strated in animal models of liver fibrosis (Aziz et al., 2007;
Zhao et al., 2005; Fang et al., 2004). MSC have a significant
impact on hepatic fibrogenesis through their ability of
inhibiting activated HSC and re-regulating the fibrogenic
process.
MSC-induced HSC apoptosis
HSCs are the major source of fibrillar collagens and other
ECM proteins that characterize liver fibrosis. Following liver
injury, HSCs undergo a phenotypic switch from quiescent,
vitamin A-storing cells into proliferative, α-smooth muscle
actin positive, myofibroblast-like cells, a process termed
activation (Friedman, 2008). Activated HSC is central to liver
fibrosis and induction of HSC apoptosis is a potential
antifibrotic treatment. This was directly evidenced in a
recent study of Parekkadan et al. (2007b). Indirect co-
culture of activated HSCs and MSC led to a significant
decrease in collagen deposition and cell proliferation, while
inducing apoptosis of activated HSCs. The underlying
mechanisms in the modulation of HSC activity by MSC were
attributed to paracrine mediators, IL-10, TNF-α and HGF.
Blockade of MSC-derived IL-10 and TNF-α abolished the
inhibitory effects of MSC on HSC proliferation and collagen
synthesis; MSC-derived HGF was responsible for the marked
induction of HSC apoptosis as determined by antibody-
neutralization studies. IL-6 secretion from activated HSCs
induced IL-10 secretion from MSC, suggesting a dynamic
response of MSC to HSCs in the microenvironment. HSC
apoptosis can also be triggered by MSC-secreted nerve
growth factor (NGF) stimulation. MSC-originated NGF was
directly identified from human MSC culture supernatant by
quantitative ELISA measurement (Chen et al., 2002). Trim
et al. (2000) found that HSCs express p75, a low affinity NGF
receptor, and respond to NGF stimulation by undergoing
apoptosis. They also identified the presence of activated HSC
in the fibrotic bands of cirrhotic human liver biopsies and
claimed p75 as a novel marker of activated HSC. The
interactions between NGF and activated HSC have been
further demonstrated in mouse models (Oakley et al., 2003;
Asai et al., 2006). Zhao et al. (2005) have provided additional
evidence that in vitro co-culture of MSC and HSC increases
the number of HSC in the G0 phase and reduces the number of
HSC in the S phase. Thus, MSC play an inhibitory role in the
process of HSC transition from the quiescent state to the
activated state. However, it is worth noting the existence of
some discrepancies in this field. Russo et al. (2006) reported
that bone marrow-derived cells significantly contributed HSC
and myofibroblast populations in the cirrhotic mouse liver.
These bone marrow-derived cells were found to be active for
collagen type I transcription. Also with murine model,
21Mesenchymal stem cells and hepatic cirrhosisHigashiyama et al. (2007) reported that there were few, if
any, bone marrow-derived cells expressing α-smooth muscle
actin ( αSMA, a marker of activated HSC) in the fibrotic liver.
Further studies are required to clarify the controversies.
MSC-mediated re-regulation of fibeogenesis
Collagen turnover and ECM remodeling is regulated by
various MMPs and their inhibitors, i.e. the tissue inhibitors
of metalloproteinases (TIMPs). MMPs and TIMPs are crucial
for matrix remodeling processes during hepatic fibrogenesis.
The balance of ECM synthesis/ECM degradation is mainly
determined by the balance of MMPs/TIMPs. During sponta-
neous recovery from liver fibrosis, there is a decrease in TIMP
expression, an increase in collagenase activity, and increase
in apoptosis of HSC. The close correlation between the
reduction of TIMP expression and apoptosis of HSC observed
in vivo highlights a potential role for TIMP in regulating HSC
survival. An in vitro study of Murphy et al. (2002) indicated
that the inhibition of apoptosis of HSC by TIMP-1 is mediated
via effects on MMP inhibition. MSC-mediated TIMP-1 reduc-
tion was demonstrated in an in vivo MSC transplantation
study in myocardial infarction rat model (Xu et al., 2005).
Comparing to the control, the expression of TIMP-1 was
significantly decreased in the infarcted myocardium, along
with declined expressions of collagen I, collagen II, TGF-β1,
and the protection of cardiac function. Similar molecular
mechanisms may apply to liver injury-healing process,
though the direct evidence is absent from liver studies. As
listed in Table 2, most MSC-secreted and fibrogenesis-related
molecules are anti-fibrogenic and this might make MSC favor
to ECM degradation rather than accumulation during ECM
remodeling. Moreover, the delicate mechanism is very
complicated and far from clear, since some MSC-derived
molecules are fibrogenic, or favor to ECM accumulation.
Di Bonzo et al. (2008) identified a significant number of
myofibroblast-like cells of human origin after transplantingTable 2 MSC-secreted and fibrogenesis-related molecules
Molecules Fibrogenesis-related
effect
Reference
HGF HSC apoptosis Parekkadan et al.,
2007a
IL-6 activate HSC Liu and Hwang,
2005
IL-10 inhibit HSC proliferation
and collagen synthesis
Parekkadan et al.,
2007a
LIF alter inflammatory
infiltrate
Linker et al., 2008
NGF HSC apoptosis Chen et al., 2002
Nitric Oxide HSC apoptosis Ren et al., 2008;
Langer et al., 2008
TGF-β2 induce IL-6 secretion Liu and Hwang,
2005
TIMPs inhibit MMPs and
activate HSC
Liu and Hwang,
2005
TNF-α inhibit HSC proliferation
and collagen synthesis
Parekkadan et al.,
2007a
VEGF stimulate collagen I
synthesis in HSC
Liu and Hwang,
2005human MSCs to the mice with liver injury. It is presumable
that the effect of MSC varies with the nature of liver injury,
time-frame of MSC application and different experimental
models. In a rat model of severe chronic liver injury, MSC
failed to reduce fibrosis and improve liver function (Carvalho
et al., 2008). Further investigations are required to identify
the factors which affect the fate of MSC in the injured area.
Clinical application and perspectives
The translation of preclinical research on MSC to clinical use
on cirrhotic patients has generated great interest, due to the
growing population of patients with advanced liver diseases
and critical shortage of available donor livers. In cardiology,
large-scale controlled and double-blinded clinical trials were
performed in a number of clinical institutes. Some studies
have demonstrated clinical benefits, whereas in others the
differences have been less significant (Assmus et al., 2006;
Lunde et al., 2006). In most MSC-related clinical trials, bone
marrow stem cells or nucleated bone marrow cells, i.e., a
mixture of different type of cells, are directionally or
systemically delivered to patients. This might be a partial
explanation for disparate outcomes in cardiological trials.
Rosenzweig (2006) described this as “mixed results from
mixed cells”. Therefore, improved clinical outcomes can be
expected if a pertinent cell population is to be chosen. There
are only a handful of clinical trials in the field of hepatology,
all of which are small-scale, uncontrolled safety and
feasibility studies (Kallis et al., 2007). Terai et al. (2006)
implemented a clinical trial on nine patients with decom-
pensated liver cirrhosis. These patients were infused with
5.2±0.63×109 autologous bone marrow cells from the
peripheral vein. At 24 weeks after transplantation, signifi-
cant improvements were observed. These improvements
included total protein, serum albumin, Child-Pugh scores,
and α-Fetoprotein and proliferating cell nuclear antigen
expression in liver biopsy tissues. Recently, Mohamadnejad
et al. performed two small scaled clinical studies. In their
first trial, four patients with decompensated liver cirrhosis
were infused 31.73×106 (mean) MSCs through a peripheral
vein (Mohamadnejad et al., 2007a). At the end of follow-up
(after 12 months), the model for end-stage liver disease
scores of two patients improved by four points and by three
points. The mean physical and mental component scales
were more than doubled by the end of follow-up. Computed
tomography (CT) showed the increase of liver volumes of
three patients by the sixth month. However, the results of
their second trial (Mohamadnejad et al., 2007b) were not
satisfactory. Four patients received 5.25×106 (mean) auto-
logous bone marrow-hematopoietic stem cells infused
through hepatic artery. Only marginal improvements were
observed in some patients. The results of their MSC
transplantation were more promising than the study of
hematopoietic stem cell transplantation. They also indicated
that hepatic artery delivery of stem cells was not a safe
procedure. Because of the lack of reliable means of
identifying transplanted stem cells in the human body
(Pearson, 2006), caution is advised during the evaluation of
the clinical outcomes.
Based on the knowledge from preclinical studies and
previous clinical trials, following considerations should be
addressed during clinical trials for cirrhotic patients: (1)
22 L.-J. Dai et al.Utilization of purified MSC population. As discussed in the
earlier section, MSC possess the abilities of hepatic engraft-
ment and hepatic differentiation, and in addition, their easy
accessibility and quick in vitro expansion make MSC an ideal
resource for clinical use. Because bone marrow-originated
fibrogenic cells play a role in the progression of liver
fibrogenesis, the use of purified MSC population could
avoid this risk. Peng et al. (2007) successfully isolated and
in vitro expanded MSC from advanced hepatitis B patients.
MSC isolated from patients share the same surface markers
and similar biological characteristics to those isolated from
healthy humans. Their study reveals the capability of
autologous MSC transplantation in patients with advanced
liver disorders. About one billion or at least one million/kg
body weight of MSCs are required for transplantation at a
time (Fox and Strom, 2008); (2) MSC passage. Longer in vitro
culture and unnecessary manipulation may introduce more
unexpected effects to ex vivo expanded MSCs. Our experi-
ence indicates that 3 to 5-passage cultures are safe and
practical. During this culture period MSC retain cytogenetic
stability, and enough number of cells can be obtained for
transplantation starting from 10 to 15 ml of bone marrow
aspirate (Zhang et al., 2007a, 2008); (3) MSC delivery route.
Intravenous infusion is the first choice under most circum-
stances. Although portal vein or hepatic artery delivery may
enhance MSC homing efficacy, precautions must be takenFigure 1 Pathogenesis of hepatic cirrhosis and possible interventio
and hepatic stellate cells (HSC) dominate the progression of hepatic
include: (1) inhibit HSC proliferation; (2) stimulate HSC apoptosis; (3)
regeneration; and (5) hepatocyte-like differentiation. Solid arrow
possible targets of various factors. (+) and (−) represent stimulationwhen catheterization is applied to cirrhotic patients; (4)
Evaluation standard. In order to objectively assess the
therapeutic effect of MSC transplantation, a standardized
criterion must be established prior to MSC administration.
Following aspects should be covered in a practical criterion:
I) patient enrollment requirement, e.g., age, gender and
type of hepatic disease; II) hepatic function assessment; III)
liver parenchyma assessment, e.g., ultrasonography, com-
puted tomography and MRI; and IV) hepatic fibrosis assess-
ment. Liver biopsy is considered to be the gold-standard
method for the assessment of liver fibrosis, but the invasive
nature and sampling error restrict it as a routine laboratory
assay. Recently, Fontana et al. (2008) established a three-
variable model to evaluate cirrhosis. Serum hyaluronic acid,
TIMP-1 and platelet count are closely correlated with Ishak
fibrosis scores based on liver biopsy samples from 513
subjects. This model can be used as a surrogate marker of
liver fibrosis. Kuo et al. (2008) and Xu and Liu (2008)
described some parameters governing the success of using
MSCs and characteristics of various delivery approaches in
their recent papers.
Fig. 1 outlines the pathogenesis of hepatic cirrhosis and
possible intervention of mesenchymal stem cells. It is likely
that mesenchymal stem cells play a part in differentiating to
hepatocytes, stimulating the regeneration of endogenous
parenchymal cells, and enhancing fibrous matrix degradation.ns of MSC. Cirrhosis is initiated by hepatic insults-induced injury,
fibrogenesis. The interventions of mesenchymal stem cells (MSC)
inhibit ECM accumulation; (4) stimulate endogenous hepatocyte
s point directions of cell change, and dashed arrows indicate
and inhibition, respectively.
23Mesenchymal stem cells and hepatic cirrhosisExploring the therapeutic potential of mesenchymal stem
cells on hepatic cirrhosis will benefit millions of people who
suffer from end-stage of chronic liver diseases. An obvious
advantage of using mesenchymal stem cells is their auto-
transplantable nature, so as to bypass the ethical hurdles and
avoid the use of expensive immunosuppression drugs. It
remains unclear about the long-term fate of the engraftment,
and some unexpected effects may be encountered during
their application. Large-scale controlled and double-blinded
clinical trials are required before this cell transplantation
becomes a regular therapy.
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